What Is New in Thyroid Cancer: The Special Issue of the Journal Cancers

Abstract

The incidence of thyroid cancer has increased over the past 3 to 4 decades. Nonetheless, the mortality from thyroid cancer has remained stable. The thyroid gland may develop nodules encompassing several types of cell proliferation, from frankly benign to very aggressive forms with many intermediate challenging variants. For this reason, there is growing interest in evaluating thyroid nodules from many points of view, from the clinical to the molecular aspects, in the search for innovative diagnostic and prognostic parameters. The aim of this Special Issue was to provide an overview of recent developments in understanding the biology and molecular oncology of thyroid tumors of follicular cell derivation and their repercussions on the diagnosis, prognosis, and therapy. The contributions of many experts in the field made up a Special Issue of Cancers journal, that focusing on different aspects, including mechanistic and functional facets, gives the status of art of clinical and biological perspectives of thyroid cancer.

Status of mental and social activities of young and middle-aged patients after papillary thyroid cancer surgery

“…HRQoL is now considered an essential measure to assess the outcomes of clinical treatments and interventions ( 14 , 15 ). Although it is widely acknowledged that PTC has a better clinical cure rate and lower death rate than other malignant diseases ( 16 – 18 ), the HRQoL status of postoperative patients with PTC is similar to or even lower than that of patients with other malignant tumors ( 19 – 21 ). Therefore, timely targeted intervention measures after surgical treatment in PTC patients have become an increasingly important goal ( 22 ).…”

Prevention of hypoparathyroidism: A step-by-step near-infrared autofluorescence parathyroid identification method

“…In China, thyroid cancer has become one of the fastest-growing malignant conditions, and its age-standardized incidence increased to 9.61/100,000 in 2015 ( 2 , 3 ). However, since more than 90% of thyroid cancers are of the differentiated type, the vast majority (>85%) of patients survive for a long time through surgery, postoperative thyroid stimulating hormone (TSH) suppression therapy, and radioactive iodine therapy ( 4 ). Hence, more attention has been paid to postoperative complications because of their impact on quality of life.…”